While in our studies we did not observe a significant difference in IC50 for all three MDM2 inhibitors between the two HCT116 colon carcinoma cell lines with and without p53 expression, Dudgeon et al. observed a considerable decrease in pharmacological potency for Nutlin-3a in p53−/− cells [15]. This evidence concerns the gene MDM2 and colon carcinoma.